In contemplating the design of a disease prevention trial among unaffected C9orf72 repeat expansion carriers, it is essential to focus on preventing both ALS and FTD, as well as, perhaps, other phenotypes (e.g. extrapyramidal disorders) that might be the first overt clinical manifestation of disease. This evidence concerns the gene C9orf72 and frontotemporal dementia.